Virginia Norris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Virginia Norris has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Claire Ambery
GlaxoSmithKline
3 shared publications- Sandra E . Kent
GlaxoSmithKline, London, UK
2 shared publications B. J. O'COnnor
Respiratory Clinical Trials London United Kingdom
1 shared publicationD. Singh
Medicines Evaluation Unit University of Manchester University Hospital of South Manchester Manchester United Kingdom
1 shared publicationDave Singh
University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester, Manchester, UK
1 shared publicationJane H Bentley
GlaxoSmithKline, Middlesex, UK
1 shared publication
Latest Publications
- Open Access
- 30 September 2014
- Published by Springer Nature in Drugs in R&D
- Vol. 14 (4) , 241-51
Use of propranolol blockade to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy volunteers: results from two randomized trials.
- 30 September 2014
- Published by Springer Nature in Drugs in R&D
- Vol. 14 (4) , 241-51
Open AccessUse of propranolol blockade to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy volunteers: results from two randomized trials.
- 20 February 2014
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 3 (4) , 305-313
Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2‐agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers
Objective: To investigate the pharmacokinetics and pharmacodynamics of inhaled GSK961081 and fluticasone propionate (FP) given alone, concurrently and as a combination blend formulation.Methods: The study was double‐blind, double‐dummy, four‐way crossover. Twenty‐four healthy volunteers took single doses of the following in randomized order: (1) GSK961081 800 µg; (2) FP 500 µg; (3) GSK961081 800 µg and FP 500 µg as a blend formulation; and (4) GSK961081 800 µg and FP 500 µg concurrently via separate inhalers. The eLung breathing simulator was also used for the in vitro characterization of the formulations.Results: There was no pharmacokinetic interaction when GSK961081 and FP were administered concurrently. Mean Cmax and AUC(0−t) of GSK961081 were lower (∼20%) and mean Cmax and AUC(0−t) of FP were higher (two fold) following GSK961081/FP blend formulation compared to concurrent or the individual components alone. There was an increase in the FP in vitro ex‐throat dose for the GSK961081/FP blend from the eLung breathing simulator. Serum cortisol suppression was greater with GSK961081/FP blend, with lower (∼10%) cortisol levels than after GSK961081 + FP concurrent or FP alone.Conclusion: GSK961081/FP blend formulation was associated with an increase in FP systemic exposure and greater serum cortisol suppression.
- 20 February 2014
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 3 (4) , 305-313
Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2‐agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers
Objective: To investigate the pharmacokinetics and pharmacodynamics of inhaled GSK961081 and fluticasone propionate (FP) given alone, concurrently and as a combination blend formulation.Methods: The study was double‐blind, double‐dummy, four‐way crossover. Twenty‐four healthy volunteers took single doses of the following in randomized order: (1) GSK961081 800 µg; (2) FP 500 µg; (3) GSK961081 800 µg and FP 500 µg as a blend formulation; and (4) GSK961081 800 µg and FP 500 µg concurrently via separate inhalers. The eLung breathing simulator was also used for the in vitro characterization of the formulations.Results: There was no pharmacokinetic interaction when GSK961081 and FP were administered concurrently. Mean Cmax and AUC(0−t) of GSK961081 were lower (∼20%) and mean Cmax and AUC(0−t) of FP were higher (two fold) following GSK961081/FP blend formulation compared to concurrent or the individual components alone. There was an increase in the FP in vitro ex‐throat dose for the GSK961081/FP blend from the eLung breathing simulator. Serum cortisol suppression was greater with GSK961081/FP blend, with lower (∼10%) cortisol levels than after GSK961081 + FP concurrent or FP alone.Conclusion: GSK961081/FP blend formulation was associated with an increase in FP systemic exposure and greater serum cortisol suppression.
- Open Access
- 1 December 2013
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. 6, 897-903
Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study
Background: GSK2190915, a 5-lipoxygenase activating protein inhibitor, inhibits the production of cysteinyl leukotrienes and leukotriene B4 and 5-oxo-6,8,11,14-eicosatetraenoic acid. We have previously reported that GSK2190915 100 mg daily inhibits early and late asthmatic responses to inhaled allergen; the effects of lower doses have not been reported. This study assessed the dose–response effects of GSK2190915 10 mg and 50 mg on the early asthmatic response (EAR) to inhaled allergen. Methods: Nineteen subjects with mild asthma and an EAR were enrolled in a randomized, double-blind, three-way crossover study of GSK2190915 10 mg, 50 mg, and placebo orally once-daily for 3 days. Allergen challenge was performed 2 hours after the third dose. Results: Compared with placebo, GSK2190915 10 mg and 50 mg caused significant, dose-dependent attenuation of the minimum forced expiratory volume at 1 second (FEV1) absolute change from baseline; mean treatment differences were 0.21 L (95% confidence interval [CI] 0.04 L, 0.38 L) and 0.41 L (95% CI 0.24 L, 0.58 L), respectively. GSK2190915 50 mg was more effective than 10 mg; mean difference between treatments was 0.20 L, (95% CI 0.03 L, 0.36 L). Compared with placebo, GSK2190915 50 mg, but not 10 mg, significantly inhibited the weighted mean FEV1 absolute change from baseline. Conclusion: GSK2190915 50 mg attenuated the EAR similarly to GSK2190915 100 mg in our previous study, suggesting 50 mg is at the top of the dose–response curve. GSK2190915 10 mg is a suboptimal dose. The EAR can be used to assess the therapeutic dose of a new treatment for asthma.
- 1 December 2013
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. 6, 897-903
Open AccessInhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study
Background: GSK2190915, a 5-lipoxygenase activating protein inhibitor, inhibits the production of cysteinyl leukotrienes and leukotriene B4 and 5-oxo-6,8,11,14-eicosatetraenoic acid. We have previously reported that GSK2190915 100 mg daily inhibits early and late asthmatic responses to inhaled allergen; the effects of lower doses have not been reported. This study assessed the dose–response effects of GSK2190915 10 mg and 50 mg on the early asthmatic response (EAR) to inhaled allergen. Methods: Nineteen subjects with mild asthma and an EAR were enrolled in a randomized, double-blind, three-way crossover study of GSK2190915 10 mg, 50 mg, and placebo orally once-daily for 3 days. Allergen challenge was performed 2 hours after the third dose. Results: Compared with placebo, GSK2190915 10 mg and 50 mg caused significant, dose-dependent attenuation of the minimum forced expiratory volume at 1 second (FEV1) absolute change from baseline; mean treatment differences were 0.21 L (95% confidence interval [CI] 0.04 L, 0.38 L) and 0.41 L (95% CI 0.24 L, 0.58 L), respectively. GSK2190915 50 mg was more effective than 10 mg; mean difference between treatments was 0.20 L, (95% CI 0.03 L, 0.36 L). Compared with placebo, GSK2190915 50 mg, but not 10 mg, significantly inhibited the weighted mean FEV1 absolute change from baseline. Conclusion: GSK2190915 50 mg attenuated the EAR similarly to GSK2190915 100 mg in our previous study, suggesting 50 mg is at the top of the dose–response curve. GSK2190915 10 mg is a suboptimal dose. The EAR can be used to assess the therapeutic dose of a new treatment for asthma.
- 31 October 2013
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 26 (5) , 574-580
Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD
- 31 October 2013
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 26 (5) , 574-580
Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD
- 8 August 2012
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 43 (2) , 177-186
The 5‐lipoxygenase‐activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma
Summary: Background: GSK2190915, a potent 5‐lipoxygenase‐activating protein inhibitor, prevents the synthesis of leukotrienes and 5‐oxo‐6,8,11,14‐eicosatetraenoic acid (5‐oxo‐ETE).Objective: To assess the effect of GSK2190915 on the allergen‐induced asthmatic responses.Methods: Nineteen eligible male subjects with mild asthma were enrolled in and completed this four‐centre, double‐blind, two‐way crossover study (ClinicalTrials.gov NCT00748306). Subjects took GSK2190915 100 mg and placebo orally once daily for 5 days in randomized order. On Day 1 and 4 they had a methacholine challenge, on Day 3 they had an inhaled allergen challenge, and on Days 4 and 6 they had sputum induction.Results: GSK2190915 attenuated the early (0–2 h) and late (4–10 h) asthmatic responses to inhaled allergen compared with placebo. There was a statistically significant attenuation of the early asthmatic response (EAR) by GSK2190915; treatment difference of GSK2190915 vs. placebo for the minimum FEV1 EAR was 0.408 L (0.205, 0.611). There was a statistically significant attenuation of the late asthmatic response (LAR) by GSK2190915; the treatment difference of GSK2190915 vs. placebo for the minimum FEV1 LAR was 0.229 L (0.041, 0.417).There was a statistically significant attenuation of allergen‐induced sputum eosinophil count on Day 4 following GSK2190915: mean treatment difference (95% CI) between GSK2190915 and placebo was −9.95% (−18.15%, −1.77%). Compared with placebo, GSK2190915 100 mg reduced median sputum LTB4 by > 90% on Days 4 and 6. There was no effect on methacholine PC20 post allergen. GSK2190915 was generally well tolerated.Conclusion and Clinical Relevance: GSK2190915 shows potential as a treatment for patients with asthma.
- 8 August 2012
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 43 (2) , 177-186
The 5‐lipoxygenase‐activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma
Summary: Background: GSK2190915, a potent 5‐lipoxygenase‐activating protein inhibitor, prevents the synthesis of leukotrienes and 5‐oxo‐6,8,11,14‐eicosatetraenoic acid (5‐oxo‐ETE).Objective: To assess the effect of GSK2190915 on the allergen‐induced asthmatic responses.Methods: Nineteen eligible male subjects with mild asthma were enrolled in and completed this four‐centre, double‐blind, two‐way crossover study (ClinicalTrials.gov NCT00748306). Subjects took GSK2190915 100 mg and placebo orally once daily for 5 days in randomized order. On Day 1 and 4 they had a methacholine challenge, on Day 3 they had an inhaled allergen challenge, and on Days 4 and 6 they had sputum induction.Results: GSK2190915 attenuated the early (0–2 h) and late (4–10 h) asthmatic responses to inhaled allergen compared with placebo. There was a statistically significant attenuation of the early asthmatic response (EAR) by GSK2190915; treatment difference of GSK2190915 vs. placebo for the minimum FEV1 EAR was 0.408 L (0.205, 0.611). There was a statistically significant attenuation of the late asthmatic response (LAR) by GSK2190915; the treatment difference of GSK2190915 vs. placebo for the minimum FEV1 LAR was 0.229 L (0.041, 0.417).There was a statistically significant attenuation of allergen‐induced sputum eosinophil count on Day 4 following GSK2190915: mean treatment difference (95% CI) between GSK2190915 and placebo was −9.95% (−18.15%, −1.77%). Compared with placebo, GSK2190915 100 mg reduced median sputum LTB4 by > 90% on Days 4 and 6. There was no effect on methacholine PC20 post allergen. GSK2190915 was generally well tolerated.Conclusion and Clinical Relevance: GSK2190915 shows potential as a treatment for patients with asthma.